Skip Navigation

A Phase IIb Clinical Trial of the Multitargeted Recombinant Adenovirus 5 CEA/MUC1/Brachyury Vaccines Tri-Ad5 and IL-15 Superagonist N-803 in Lynch syndrome

Brief Summary

Type:
Other

Study Type:
Prevention

Phase:
II

ClinicalTrials.gov Identifier:
NCT05419011

Study #:
STUDY00148763

Start Date:
Apr 10, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05419011

View Complete Trial Details & Eligibility at ClinicalTrials.gov